28 October 2009

2009 Mesoblast Annual Report

 

Printable version of the 2009 Mesoblast Annual Report

 

17 October 2008

2008 Mesoblast Annual Report

 

28 September 2007

2007 Mesoblast Annual Report

 

29 September 2006

2006 Mesoblast Annual Report

 

14 October 2005

2005 Mesoblast Annual Report

 

Investor Centre


 
Last Share Price

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

23 August 2010 - EGM documents - Letter from the Chairman, Notice of Meeting, Independent Expert Report.

16 August - Mesoblast on track for phase 3 bone marrow transplant trial following positive meeting with FDA

21 July - Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products

12 July - Phase 3 meeting scheduled with FDA following positive results of bone marrow regeneration trial

28 May - Mesoblast featured at ASX Singapore conference highlighting emerging market leaders

19 May - United States FDA Clears Phase 2 Trial for Cervical Spinal Fusion

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine
 

 

© Copyright Mesoblast Limited 2010. All rights reserved.
Website design by Infoprobe Australia

disclaimer | privacy policy

home | contact | sitemap | Angioblast Systems | webmail
the company | the technology | product development | investor centre | news room